Clinically approved ICIs include anti–PD-1 antibodies (pembrolizumab, nivolumab), anti–PD-L1 antibodies (atezolizumab), and anti–CTLA-4 antibodies (ipilimumab), all of which have demonstrated durable responses in various cancers [33]. Here, CTLA4 is linked to cancer.